• Lilly J H Brada, Thijs J Schouten, Lois A Daamen, Leonard W F Seelen, Marieke S Walma, Ronald van Dam, Ignace H de Hingh, LiemMike S LMSLDepartment of Surgery, Medical Spectrum Twente, Enschede, the Netherlands., Vincent E de Meijer, Gijs A Patijn, Sebastiaan Festen, StommelMartijn W JMWJDepartment of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands., Koop Bosscha, Marc G Besselink, Hjalmar C van Santvoort, Izaak Quintus Molenaar, and Dutch Pancreatic Cancer Group.
• Department of Surgery, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands.
• Ann. Surg. 2024 Apr 1.

ObjectiveThis study aims to evaluate short- and long-term outcomes following pancreatectomy in patients with LAPC compared to (B)RPC patients.Summary Background DataSelected patients diagnosed with locally advanced pancreatic cancer (LAPC) are increasingly undergoing resection following induction chemotherapy. To evaluate the benefit of this treatment approach, it is helpful to compare outcomes in resected patients with primary LAPC to outcomes in resected patients with primary (borderline) resectable pancreatic cancer ((B)RPC).MethodsTwo prospectively maintained nationwide databases were used for this study. Patients with (B)RPC undergoing upfront tumor resection and patients with resected LAPC after induction therapy were included. Outcomes were postoperative pancreas-specific complications, 90-day mortality, pathological outcomes, disease-free interval (DFI), and overall survival (OS).ResultsOverall, 879 patients were included; 103 with LAPC (12%) and 776 with (B)RPC (88%). LAPC patients had a lower WHO performance score and CACI. Postoperative pancreas-specific complications were comparable between groups, except delayed gastric emptying grade C, which occurred more often in LAPC patients (9% vs. 3%, P=0.03). Ninety-day mortality was comparable. About half of the patients in both groups (54% in LAPC vs. 48% in (B)RPC), P=0.21) had a radical resection (R0). DFI was 13 months in both groups (P=0.12) and OS from date of diagnosis was 24 months in LAPC patients and 19 months in (B)RPC patients (P=0.34).ConclusionsIn our nationwide prospective databases, pancreas-specific complications, mortality and survival in patients with LAPC following pancreatectomy are comparable with those undergoing resection for (B)RPC. These outcomes suggest that postoperative morbidity and mortality after tumor resection in carefully selected patients with LAPC are acceptable.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

19 keywords...

hide…